InMed

InMed is a clinical-stage company developing a pipeline of cannabinoid-based drug candidates. InMed is a leader in the manufacturing and development of rare cannabinoids. Our manufacturing technology produces several rare cannabinoids for pharmaceutical development and consumer goods. Alongside InMed's dermatological and ocular disease treatment development programs, InMed is developing a cannabinoid synthesis manufacturing system called IntegraSynTM to produce cost-effective, pharmaceutical-grade, bioidentical cannabinoids. Plant extraction cannot meet the long-term drug needs of cannabinoid therapies, especially for rare cannabinoids. InMed’s products are designed to be bioidentical to naturally occurring cannabinoids. Compared to alternative methods, this process aims to save costs and time while allowing for greater ease, control, and quality during manufacturing.